Hematopoietic Cell Transplant Co-Morbidity Index (HCT-CI): Ability to Predict
Outcomes in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)
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Introduction

Results

Discussion/Conclusion

We developed a 2 step approach to HI HSCT in which a
fixed dose of allogeneic T cells are infused after reduced
intensity (RIC) or myeloablative conditioning (HSCT step 1).
After 2-3 days, cyclophosphamide (CY) 60 mg/kg/d x 2 is
given to establish bidirectional tolerance. One day after the
CY, a CD 34 selected stem cell product is infused (HSCT
step 2).

We identified 157 pts; 61 female, 96 male, median age
55 (range 19-78), 34% undergoing RIC HSCT with
complete HCT-CI data who were transplanted from
2007 through 2013. 23 pts (15%) had a HCT-CI score
of 0, 55 (35%) had a score of 1-2, and 79 (50%) had a
score of ≥ 3. A HCT-CI score of 0 was associated with a
significantly increased OS (p=0.039) with median
survival not reached for HCT-CI score 0 or score 1-2
versus 21 months with score ≥ 3 (fig. 1). We also
examined the predictability of the HCT-CI on OS of pts
with (54%) versus without (46%) disease at HSCT, and
found that differences (figures 2-3) between HCT-CI
groups were limited to pts with disease at time of HSCT
(p=0.003 vs p=0.765). Twenty nine of 157 (19 %) died of
NRM: 3 pts (10%) in the 0, 8 (28%) in the 1-2, and 18
(62%) in the ≥ 3 score groups respectively.

This analysis of the HCT-CI suggests its ability to correctly
identify pts in the lowest score category as being at
decreased risk for mortality. Predictability of OS in pts with
higher scores was limited to those with disease at the time
of HSCT. There was also a suggestion that higher scores
correlated with increased rates of NRM. Of note, both the
percent of pts with ≥3 points and their OS was higher in the
2 step group than what was reported by Sorror et al in 2005.
While we believe this is due in part to the low NRM
associated with the 2 step method even in higher risk
groups, we also note that more of the 2 step pts had 2-3
points for low PFTs (80% vs 33%). This indicates that the
calculation of pulmonary function as measured at our
institution may have inflated the high risk numbers, affecting
optimal use of the tool. Next steps include assessing PFT
methodology as it affects the HCT-CI as well as assessing
the utility of other comorbidity indices in conjunction with the
HCT-CI, including Karnofsky performance score.

This approach has been associated with a low incidence of
non-relapse mortality (NRM) resulting in a significant
improvement in overall survival (OS) in patients (pts)
undergoing HI HSCT at our institution. This abstract
examined the predictability of this tool in pts undergoing the
2 step HI HSCT.

Methods
We retrospectively analyzed pts treated on 2-step HI
protocols. Groups were divided into 3 previously described
risk groups: 0, 1-2, and ≥ 3. Survival data was calculated
according to Kaplan-Meier methods.

